共 50 条
- [1] PHASE 1B DOSE ESCALATION STUDY OF ORAL QUISINOSTAT, A HISTONE DEACETYLASE INHIBITOR, IN COMBINATION WITH VELCADE (BORTEZOMIB) AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED MULTIPLE MYELOMAHAEMATOLOGICA, 2013, 98 : 103 - 103Moreau, P.Facon, T.Benboubker, L.Touzeau, C.Delain, M.Fourneau, N.Phelps, C.Forslund, A.Hellemans, P.Smit, H.Badamo-Dotzis, J.Leleu, X.
- [2] Phase 1b Dose Escalation Study Of Oral Quisinostat, a Histone Deacetylase Inhibitor (HDACi), In Combination With Velcade (Bortezomib) and Dexamethasone For Patients With Relapsed Multiple Myeloma (MM)BLOOD, 2013, 122 (21)Moreau, PhilippeFacon, ThierryTouzeau, CyrilleBenboubker, LotfiDelain, MartineBadamo-Dotzis, JuliePhelps, CharlesDoty, ChristopherSmit, HansFourneau, NeleForslund, AnnHellemans, PeterLeleu, Xavier
- [3] Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myelomaLEUKEMIA & LYMPHOMA, 2016, 57 (07) : 1546 - 1559Moreau, PhilippeFacon, ThierryTouzeau, CyrilleBenboubker, LotfiDelain, MartineBadamo-Dotzis, JuliePhelps, CharlesDoty, ChristopherSmit, HansFourneau, NeleForslund, AnnHellemans, PeterLeleu, Xavier
- [4] Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple MyelomaCLINICAL CANCER RESEARCH, 2017, 23 (13) : 3307 - 3315Vogl, Dan T.Raje, NoopurJagannath, SundarRichardson, PaulHari, ParameswaranOrlowski, RobertSupko, Jeffrey G.Tamang, DavidYang, MinJones, Simon S.Wheeler, CatherineMarkelewicz, Robert J.Lonial, Sagar
- [5] A PHASE IB DOSE-ESCALATION STUDY OF ORAL PANOBINOSTAT (LBH589) AND IV BORTEZOMIB IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMAHAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 155 - 155San Miguel, J.Sezer, O.Siegel, D.Guenther, A.Blade, J.Prosser, I.Hazell, K.Bengoudifa, R.Klebsattel, M.Bourquelot, P.Cavo, M.Goebeler, M.Niederweiser, D.Milder, M.Boccadoro, M.Anderson, K.
- [6] Phase II Study of the Pan-Deacetylase Inhibitor Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and Bortezomib-Refractory Multiple Myeloma (PANORAMA 2)BLOOD, 2011, 118 (21) : 370 - 371Richardson, Paul G.Alsina, MelissaWeber, Donna M.Coutre, Steven E.Lonial, SagarGasparetto, CristinaWarsi, GhulamOndovik, MichaelMukhopadhyay, SutapaSnodgrass, SusanSchlossman, Robert
- [7] Phase I dose-escalation study of cyclophosphamide combined with bortezomib and dexamethasone in Japanese patients with relapsed and/or refractory multiple myelomaINTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 102 (04) : 434 - 440Sugiura, IsamuTerabe, SatomiKinoshita, TomohiroYamamoto, KazuhitoSawa, MasashiOzawa, YukiyasuAtsuta, YoshikoSuzuki, RitsuroShimizu, Kazuyuki
- [8] Phase I dose-escalation study of cyclophosphamide combined with bortezomib and dexamethasone in Japanese patients with relapsed and/or refractory multiple myelomaInternational Journal of Hematology, 2015, 102 : 434 - 440Isamu SugiuraSatomi TerabeTomohiro KinoshitaKazuhito YamamotoMasashi SawaYukiyasu OzawaYoshiko AtsutaRitsuro SuzukiKazuyuki Shimizu
- [9] Bortezomib in combination with dexamethasone for relapsed multiple myelomaLEUKEMIA RESEARCH, 2005, 29 (05) : 587 - 590Kropff, MHBisping, GWenning, DVolpert, STchinda, JBerdel, EWKienast, J
- [10] A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myelomaEUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (05) : 435 - 442Hajek, RomanPour, LudekOzcan, MuhitSanchez, Jesus MartinSanz, Ramon GarciaAnagnostopoulos, AchillesOriol, AlbertCascavilla, NicolaTerjung, AndreasLee, YihuaBriso, Eva M.Dobkowska, EdytaHauns, BernhardSpicka, Ivan